A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer
Phase of Trial: Phase II
Latest Information Update: 08 Apr 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms RAMONA
- 08 Apr 2019 Planned End Date changed from 1 Jan 2021 to 1 Apr 2021.
- 08 Apr 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Dec 2019.
- 14 Mar 2019 Trial design published in the BMC Cancer